Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program

BACKGROUND: The Italian Renal Cell Cancer Early Access Program was an expanded access program that allowed access to nivolumab, for patients (pts) with metastatic renal cell carcinoma (mRCC) prior to regulatory approval. METHODS: Pts with previously treated advanced or mRCC were eligible to receive...

Full description

Saved in:
Bibliographic Details
Published in:J Immunother Cancer
Main Authors: Verzoni, Elena, Cartenì, Giacomo, Cortesi, Enrico, Giannarelli, Diana, De Giglio, Andrea, Sabbatini, Roberto, Buti, Sebastiano, Rossetti, Sabrina, Cognetti, Francesco, Rastelli, Francesca, Sobrero, Alberto, Turci, Daniele, Sternberg, Cora N., Porta, Camillo, Cappuzzo, Federico, Tortora, Giampaolo, Tassinari, Davide, Panni, Stefano, Pazzola, Antonio, Surico, Gianmarco, Raimondi, Alessandra, De Giorgi, Ugo, Procopio, Giuseppe
Format: Artigo
Language:Inglês
Published: BioMed Central 2019
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6448290/
https://ncbi.nlm.nih.gov/pubmed/30944023
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0579-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items